Pages that link to "Q43504310"

The following pages link to Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications (Q43504310):

Displaying 33 items.

• Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma (Q24650785) (← links)
• Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer (Q28253632) (← links)
• Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission (Q33723714) (← links)
• Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma (Q34103053) (← links)
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. (Q34241661) (← links)
• DNA methylation in multiple myeloma is weakly associated with gene transcription (Q34534256) (← links)
• How I treat smoldering multiple myeloma (Q34580094) (← links)
• Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma (Q34580260) (← links)
• Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf (Q34795181) (← links)
• Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression (Q35126641) (← links)
• Deoxyribonucleic acid (DNA) methyltransferase contributes to p16 promoter CpG island methylation in lung adenocarcinoma with smoking (Q36317675) (← links)
• Genetic events in the pathogenesis of multiple myeloma (Q36380235) (← links)
• Prevalence of p16 methylation and prognostic factors in plasma cell myeloma at a single institution in Korea (Q36502674) (← links)
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (Q36889961) (← links)
• Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. (Q37006888) (← links)
• Genomic and proteomic biomarkers for cancer: a multitude of opportunities. (Q37363928) (← links)
• Centrosomes and myeloma; aneuploidy and proliferation. (Q37384474) (← links)
• TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms (Q37672563) (← links)
• DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer (Q37796732) (← links)
• Pathogenesis of Myeloma (Q37831905) (← links)
• The genetic architecture of multiple myeloma. (Q38001913) (← links)
• The role of epigenetics in the biology of multiple myeloma. (Q38208520) (← links)
• Gene integrated set profile analysis: a context-based approach for inferring biological endpoints (Q38798005) (← links)
• Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. (Q40914883) (← links)
• Understanding the multiple biological aspects leading to myeloma (Q42385107) (← links)
• Methylation status of nine tumor suppressor genes in multiple myeloma (Q43206588) (← links)
• Clinicopathological significance of the p16 hypermethylation in multiple myeloma, a systematic review and meta-analysis (Q47126735) (← links)
• The therapeutic potential of cell cycle targeting in multiple myeloma (Q47203904) (← links)
• Immunohistochemical expression of cell cycle proteins in multiple myeloma. (Q53649136) (← links)
• Aberrant gene promoter methylation in plasma cell dyscrasias (Q81079624) (← links)
• Indirect Tumor Inhibitory Effects of MicroRNA-124 through Targeting EZH2 in The Multiple Myeloma Cell Line (Q90674642) (← links)
• Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options (Q91636854) (← links)
• Histone deacetylase inhibitors in multiple myeloma (Q93541719) (← links)